| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Hall, J Murrell, A Ogunniyi, M Deeg, O Baiyewu, S Gao, O Gureje, J Dickens, R Evans, V Smith-Gamble, F W Unverzagt, J Shen, H Hendri. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology. vol 66. issue 2. 2006-03-14. PMID:16434658. |
to examine the relationship between cholesterol and other lipids, apoe genotype, and risk of alzheimer disease (ad) in a population-based study of elderly yoruba living in ibadan, nigeria. |
2006-03-14 |
2023-08-12 |
Not clear |
| Micha M M Wilhelmus, Irene Otte-Höller, Judianne Davis, William E Van Nostrand, Robert M W de Waal, Marcel M Verbee. Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 14. 2006-03-01. PMID:15814793. |
the epsilon4 allele of apolipoprotein e (apoe) is a risk factor for alzheimer's disease (ad), whereas the epsilon2 allele may be relatively protective. |
2006-03-01 |
2023-08-12 |
Not clear |
| Xuemei Huang, Peter Chen, Daniel I Kaufer, Alexander I Tröster, Charles Pool. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Archives of neurology. vol 63. issue 2. 2006-02-28. PMID:16476806. |
to understand the relationship of apolipoprotein e (apoe) polymorphism to dementia in parkinson disease (pd) because the apoe epsilon4 allele is linked to alzheimer disease. |
2006-02-28 |
2023-08-12 |
Not clear |
| Veronica Hirsch-Reinshagen, Luis F Maia, Braydon L Burgess, Jean-Francois Blain, Kathryn E Naus, Sean A McIsaac, Pamela F Parkinson, Jennifer Y Chan, Gavin H Tansley, Michael R Hayden, Judes Poirier, William Van Nostrand, Cheryl L Wellingto. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. The Journal of biological chemistry. vol 280. issue 52. 2006-02-27. PMID:16207707. |
the absence of abca1 decreases soluble apoe levels but does not diminish amyloid deposition in two murine models of alzheimer disease. |
2006-02-27 |
2023-08-12 |
mouse |
| Suzanne E Wahrle, Hong Jiang, Maia Parsadanian, Richard E Hartman, Kelly R Bales, Steven M Paul, David M Holtzma. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. The Journal of biological chemistry. vol 280. issue 52. 2006-02-27. PMID:16207708. |
apolipoprotein e (apoe) genotype has a major influence on the risk for alzheimer disease (ad). |
2006-02-27 |
2023-08-12 |
mouse |
| Radosveta Koldamova, Matthias Staufenbiel, Iliya Leftero. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. The Journal of biological chemistry. vol 280. issue 52. 2006-02-27. PMID:16207713. |
apoe isoforms strongly affect alzheimer disease (ad) pathology and risk. |
2006-02-27 |
2023-08-12 |
mouse |
| Mark A Sager, Bruce Hermann, Asenath La Ru. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Journal of geriatric psychiatry and neurology. vol 18. issue 4. 2006-02-24. PMID:16306248. |
middle-aged children of persons with alzheimer's disease: apoe genotypes and cognitive function in the wisconsin registry for alzheimer's prevention. |
2006-02-24 |
2023-08-12 |
human |
| Mark A Sager, Bruce Hermann, Asenath La Ru. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Journal of geriatric psychiatry and neurology. vol 18. issue 4. 2006-02-24. PMID:16306248. |
the high percentage of wrap participants who are carriers of apoe epsilon4 underscores their increased risk for developing alzheimer's disease, but the absence of differences related to apoe status and high mean scores on cognitive tests suggests that the apoe epsilon4 gene has yet to have a clinical impact on cognitive functioning. |
2006-02-24 |
2023-08-12 |
human |
| Benedetta Nacmias, Silvia Bagnoli, Andrea Tedde, Elena Cellini, Bianca Maria Guarnieri, Antonella Bartoli, Antonio Serio, Silvia Piacentini, Sandro Sorb. Cystatin C and apoe polymorphisms in Italian Alzheimer's disease. Neuroscience letters. vol 392. issue 1-2. 2006-02-23. PMID:16188386. |
cystatin c and apoe polymorphisms in italian alzheimer's disease. |
2006-02-23 |
2023-08-12 |
human |
| George Bartzokis, Po H Lu, Daniel H Geschwind, Nancy Edwards, Jim Mintz, Jeffrey L Cumming. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Archives of general psychiatry. vol 63. issue 1. 2006-02-15. PMID:16389198. |
apolipoprotein e (apoe) genotype is the most influential alzheimer disease (ad) risk factor after advanced age. |
2006-02-15 |
2023-08-12 |
human |
| Shiming Ye, Yadong Huang, Karin Müllendorff, Liming Dong, Gretchen Giedt, Elaine C Meng, Fred E Cohen, Irwin D Kuntz, Karl H Weisgraber, Robert W Mahle. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. vol 102. issue 51. 2006-01-31. PMID:16344478. |
apolipoprotein (apo) e4 is a major risk factor for alzheimer's disease, and many studies have suggested that apoe has isoform-specific effects on the deposition or clearance of amyloid beta (abeta) peptides. |
2006-01-31 |
2023-08-12 |
human |
| Paolo Bosco, Rosa-Maria Guéant-Rodríguez, Guido Anello, Rosario S Spada, Antonino Romano, Filippo Caraci, Raffaele Ferri, Jean-Louis Guéan. Allele epsilon 4 of APOE is a stronger predictor of Alzheimer risk in Sicily than in continental South Italy. Neuroscience letters. vol 388. issue 3. 2006-01-23. PMID:16040191. |
allele epsilon 4 of apoe is a stronger predictor of alzheimer risk in sicily than in continental south italy. |
2006-01-23 |
2023-08-12 |
Not clear |
| Daniela Fenili, Joanne McLauri. Cholesterol and apoe: a target for Alzheimer's disease therapeutics. Current drug targets. CNS and neurological disorders. vol 4. issue 5. 2006-01-23. PMID:16266288. |
cholesterol and apoe: a target for alzheimer's disease therapeutics. |
2006-01-23 |
2023-08-12 |
Not clear |
| Katharina Buerger, Stefan J Teipel, Raymond Zinkowski, Trey Sunderland, Niels Andreasen, Kaj Blennow, Michael Ewers, John DeBernardis, Yong Shen, Daniel Kerkman, Yansheng Du, Harald Hampe. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Neuroscience letters. vol 391. issue 1-2. 2006-01-20. PMID:16165272. |
we investigated the correlation between the apolipoprotein e varepsilon4 allele (apoe epsilon4) carrier status, a major risk factor of alzheimer's disease (ad), and levels of tau protein phosphorylated at threonine 231 (p-tau(231p)) in cerebrospinal fluid (csf) in predementia and clinical stages of ad and healthy controls (hc). |
2006-01-20 |
2023-08-12 |
human |
| David Melzer, M G Dik, Gerard J van Kamp, Cees Jonker, Dorly J Dee. The apolipoprotein E e4 polymorphism is strongly associated with poor mobility performance test results but not self-reported limitation in older people. The journals of gerontology. Series A, Biological sciences and medical sciences. vol 60. issue 10. 2006-01-13. PMID:16282567. |
the apolipoprotein e (apoe) e4 polymorphism is linked to increased mortality rates, alzheimer's disease, and cardiovascular disease in older people, but previous studies have largely failed to detect an effect on self-reported mobility disability. |
2006-01-13 |
2023-08-12 |
Not clear |
| Nicholas J Bray, Luke Jehu, Valentina Moskvina, Joseph D Buxbaum, Stella Dracheva, Vahram Haroutunian, Julie Williams, Paul R Buckland, Michael J Owen, Michael C O'Donova. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Human molecular genetics. vol 13. issue 22. 2006-01-12. PMID:15385439. |
the epsilon4 haplotype of apoe is the only undisputed genetic risk factor for late-onset alzheimer's disease (load). |
2006-01-12 |
2023-08-12 |
human |
| Alfred Rapp, Manfred Hüttinge. Role of chondroitin sulphate in the uptake of beta-VLDL by brain cells. The European journal of neuroscience. vol 22. issue 6. 2006-01-10. PMID:16190894. |
at the same time, proteoglycans, apoe as well as lipoprotein receptors have been reported to be constituents of amyloid plaques, one hallmark of alzheimer's disease. |
2006-01-10 |
2023-08-12 |
Not clear |
| Liana Lisboa Fernandez, Rosane Machado Scheib. Is MTHFR polymorphism a risk factor for Alzheimer's disease like APOE? Arquivos de neuro-psiquiatria. vol 63. issue 1. 2006-01-05. PMID:15830056. |
is mthfr polymorphism a risk factor for alzheimer's disease like apoe? |
2006-01-05 |
2023-08-12 |
Not clear |
| A G Yip, A C McKee, R C Green, J Wells, H Young, L A Cupples, L A Farre. APOE, vascular pathology, and the AD brain. Neurology. vol 65. issue 2. 2006-01-04. PMID:16043796. |
to use neuropathologic data to examine the association between apoe genotype and cerebrovascular lesions commonly found in alzheimer disease (ad), as well as neuritic senile plaque (sp) and neurofibrillary tangle (nft) burden. |
2006-01-04 |
2023-08-12 |
Not clear |
| Nancy C Stratman, Christine K Castle, Bruce M Taylor, Dennis E Epps, George W Melchior, Donald B Carte. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chemistry and physics of lipids. vol 137. issue 1-2. 2005-12-07. PMID:16140289. |
brain plaque deposits of amyloid-beta peptide (abeta) is a pathological hallmark of alzheimer's disease (ad) and apolipoprotein e (apoe) is thought to be involved in its deposition. |
2005-12-07 |
2023-08-12 |
human |